Pharmaceutical Technology on MSN

GLP-1RA Alzheimer’s hopes dashed after Novo Nordisk’s semaglutide miss

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the ...
Pharmaceutical Technology on MSN

WHO backs use of GLP-1RAs for weight loss despite shortage warning

The World Health Organization (WHO) predicts that fewer than 10% of eligible patients will have access to GLP-1RAs by 2030.

GLP-1RAs shown to reduce risk of cardiovascular death

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed ...

Weight-loss drugs like Ozempic and Wegovy tied to another debilitating side effect

A new study reveals that diabetes and weight loss drugs known as GLP-1s are lined with an increased risk of a chronic ...

Patients who discontinue GLP-1s found to have more weight gain, complications during pregnancy

In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 ...

7MM Metabolic Dysfunction-Associated Steatohepatitis Drug Analysis and Forecast Report 2022-2032: Growth Driven by GLP-1RA Launches Such as Semaglutide and Rising Adoption of ...

Key opportunities in the MASH market include the anticipated launch of new pipeline agents, particularly GLP-1RA drugs like semaglutide, increased prevalence of MASH, and rising use of non-invasive ...

Pharma’s post-Covid run faces a reality check

Pharma's post-Covid growth faces challenges as margin compression and strategic shifts emerge in 2026, urging a bottom-up ...